Net Income

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Cineplex expands its free popcorn event to four days, a strategic move to leverage its loyalty program and combat the post-holiday attendance slump.

Palladyne AI launches its IQ 2.0 software, a low-code platform aiming to overhaul defense manufacturing in line with new government mandates.

After a lengthy battle, a New York financier is cleared of all charges. Now, his lawsuit against FINRA and Capital Group challenges the system itself.

Utz Brands posted strong 2025 profit growth and market share gains, overcoming retail inventory issues caused by economic headwinds like SNAP delays.

Cytek Biosciences reports preliminary 2025 revenue of $201M, beating estimates with a major Q4 growth surge ahead of its key J.P. Morgan presentation.

West Red Lake Gold officially begins commercial production at its historic Madsen Mine, signaling a new era of gold output in the prolific Red Lake district.

The deepwater oil firm is refinancing its debt, extending maturities and tapping new markets to bolster its finances amid market volatility and analyst concerns.

A federal plan for the Colorado River's future ignites fears of 'dramatic cuts' for 20 million Californians and threatens a multi-state legal war.

The western wear retailer posted a 16% sales jump and a nearly 20% surge in e-commerce, signaling robust growth ahead of its ICR Conference appearance.

As WD-40 leaders prepare for the ICR Conference, investors weigh strong growth plans against a recent earnings miss and a major brand overhaul.

Facing a Nasdaq delisting notice, social commerce firm Webuy Global has 45 days to devise a plan to fix its $2.1M stockholders' equity deficiency.

MES Life Safety has offloaded its alleged PFAS liabilities to a third party, a strategic move to de-risk its finances and focus on its core mission.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.